The global preclinical imaging In-VIVO systems and reagents market is expected to exceed US$ 960 million by 2022, registering a compound annual growth rate (CAGR) of more than 6% during the forecast period. The technological advancements in the field of molecular imaging, increasing market demand for noninvasive small animal imaging techniques, and growing number of public-private initiatives and funding to support preclinical researches are driving the market. However, stringent regulations governing preclinical research and significant installation and operational costs associated with preclinical imaging modalities are expected to hamper the growth of the market during the forecast period.
In this report, the global preclinical imaging In-VIVO systems and reagents market is segmented by modality, reagent, and region. On the basis of modality, the market is segmented into optical imaging systems, standalone fluorescence imaging systems, bioluminescence/fluorescence imaging systems, optical + x-ray/optical + CT, micro-PET systems, preclinical nuclear imaging systems, micro-MRI systems, trimodality (SPECT/PET/CT) systems, micro-SPECT systems micro-CT systems, micro-ultrasound systems, preclinical magnetic particle imaging (MPI) systems, and preclinical photo acoustic imaging systems. The market on the basis of reagent is segmented into preclinical optical imaging, fluorescent imaging, bioluminescent imaging, preclinical nuclear imaging, preclinical SPECT probes, preclinical MRI contrast agents, preclinical PET tracers, gadolinium-based preclinical MRI contrast agents, manganese-based preclinical MRI contrast agents, iron-based preclinical MRI contrast agents, preclinical CT contrast agents, barium-based preclinical CT contrast agents, preclinical ultrasound contrast agents, gold nano particles, iodine-based preclinical CT contrast agents, and gastrografin-based preclinical CT contrast agents.
The global preclinical imaging In-VIVO systems and reagents market is segmented on the basis of key regions, namely, North America, Europe, Asia Pacific, and Rest of the World. Furthermore, each region is segmented to provide market revenue for select countries such as the U.S., Canada, the U.K., Germany, China, Japan, India, Brazil, and GCC countries. The report includes a detailed study of the global and regional market and analyzes the variations in the growth of the industry in certain regions.
A glimpse of the report structure is provided in the report description available on the website.
Aspect Imaging Ltd, Bruker Corporation, Fujifilm Holdings Corporation, Li-Cor Biosciences, MR Solutions Ltd., Mediso Ltd., Milabs B.V., MiltenyiBiotec GmbH, and PerkinElmer and Trifoil Imaging are the most active players in the preclinical imaging In-VIVO systems and reagents market.
This report covers the preclinical imaging In-VIVO systems and reagents market, in terms of value, and forecasts the market size till 2022. In addition, the report identifies key growth segments and opportunities in the industry. This report also covers detailed competitive outlook including the share and company profiles of the key players in the global market. Company profile includes company summary, financial summary, business strategy and planning, SWOT analysis, and current developments.
Company Name: Market Research Engine
Contact Person: John Bay
Country: United States
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com